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Background: Despite the fact that the implication of human papillomavirus (HPV) in the carcinogenesis and
prognosis of cervical cancer is well established, the impact of a co-infection with high risk HPV (HR-HPV) and
Epstein-Barr virus (EBV) is still not fully understood.
Methods: Fifty eight randomly selected cases of squamous cell carcinomas (SCC) of the uterine cervix, 14 normal
cervices specimens, 21 CIN-2/3 and 16 CIN-1 cases were examined for EBV and HPV infections. Detection of HR-HPV
specific sequences was carried out by PCR amplification using consensus primers of Manos and by Digene Hybrid
Capture. The presence of EBV was revealed by amplifying a 660 bp specific EBV sequence of BALF1. mRNA
expression of LMP-1 in one hand and protein levels of BARF-1, LMP-1 and EBNA-1 in the other hand were
assessed by RT-PCR and immunoblotting and/or immunohischemistry respectively.
Results: HR-HPV infection was found in patients with SCC (88%), low-grade (75%) and high grade (95%) lesions
compared to only 14% of normal cervix cases. However, 69%, 12.5%, 38.1%, and 14% of SCC, CIN-1, CIN-2/3 and
normal cervix tissues, respectively, were EBV infected. The highest co-infection (HR-HPV and EBV) was found in
squamous cell carcinoma cases (67%). The latter cases showed 27% and 29% expression of EBV BARF-1 and LMP-1
oncogenes respectively.
Conclusion: The high rate of HR-HPV and EBV co-infection in SCC suggests that EBV infection is incriminated in
cervical cancer progression. This could be taken into account as bad prognosis in this type of cancer. However, the
mode of action in dual infection in cervical oncogenesis needs further investigation.
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Cervical cancer is the second most prevalent cancer
among the Algerian women. The association between
human papilomavirus (HPV) and cervical neoplasia is
well documented [1]. High risk oncogenic HPV types
(including HPV 16 and HPV 18) are associated with
99.7% of all low-grade cervical (CIN-1 or mild CIN) and
high grade intraepithelial lesions (CIN-2/3) and hence,
they play an important role in cervical cancer develop-
ment. Now, and since 1976, it is well recognized that* Correspondence: tadamasa.ooka@univ-lyon1.fr
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distribution, and reproduction in any mediumHPV infections in the cervix are frequently associated
with intraepithelial neoplasia and invasive squamous
cell carcinomas (SCC) with all their different histo-
logical variants (large-cell keratinizing, large-cell non-
keratinizing and small-cell carcinoma).
The long period of time (years) it takes for the
development of cervical cancer after HPV infection
suggests the involvement of other etiologies (such as
viruses or cell compounds) in malignancy process.
The synergistic effect of carcinogenic factors such as
two or more viruses interacting at different stages of
tumor development has been reported [2-4]. Epstein-
Barr virus (EBV), ubiquitous human gamma-herpes
virus responsible for mononucleosis [5], could be oneentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Distribution of EBV and HR-HPV in patients with either
cervical precancerous or cancerous lesions compared to normal
subjects. High risk human papillomavirus were detected by PCR
(using consensus primers) and by Hybrid Capture 2 (Digene).
Epstein-Barr virus was detected by PCR using primers that amplify
the entire BALF-1 gene. Percentage in ordinate; Normal cervix,
cervical lesions and carcinoma cases in Abscissa. NC: normal cervixes;
CIN-2/3: High-grade cervical lesions; CIN-1: Low-grade cervical
lesions; SCC: squamous cell carcinoma.
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[5] and replicates in cervix cells [6]. EBV infection,
widely spread among the population [7,8], has been
associated with an increasing number of lymphocytic
and epithelial cancers, mainly Burkitt’s lymphoma,
Hodgkin’s lymphoma, T cell lymphoma, nasopharyn-
geal carcinoma (NPC) and gastric adenocarcinoma [9,10].
BARF1 is one of the EBV-encoded proteins secreted
in the serum of NPC patients [11] and expressed in
more than 90% of NPC biopsies [12-15] and tumor
epithelial cells of EBV-associated gastric carcinoma
[12]. It has a malignant transforming activity in
rodent fibroblasts [16] and in EBV-negative human
B cells [14]. LMP1, another EBV oncogene candidate
essential for B cell immortalization [17], was present
in 30 to 50% of NPC biopsies [18]. This oncogene
can activate a number of cellular key genes such as
NFκB and EGFR [17,19]. LMP-1 can inhibit cell dif-
ferentiation when transfected into epithelial cells [18].
Tseng et al. [20] reported a high incidence of EBV
in lymphoepithelial like-carcinoma (LELC) patients
but did not show any association with HPV. These
findings are in contradiction with what has been
previously reported [21,22]. Therefore, the oncogenic
relationship between the two viruses remains not fully
understood. Added to this, the presence of EBV in the
cervix carcinoma remains equally a topic of great
debate among virologists, confirmed by certain au-
thors [2,23,24] but not by others [25,26].
As it is well known EBV can transform cells bearing
the EBV/C3d receptor making them receptive to other
oncogenic stimuli [27]. These receptors are widely
detected on ecto- and endo-cervical biopsies of the
uterine cervix [28-30]. EBV replicates in cervical epi-
thelium and its possible role in cervical carcinoma
development has been raised.
We looked, in this study, for the presence of both
EBV and HPV DNA sequences in Algerian patients
with SCC and cervical lesions. We examined the
presence of EBV infection and the EBV-HPV co-
infection. The presence of EBV in cervical cancer tis-
sues suggests its possible involvement in the cervical
cancer progression. Initially, PCR amplification was
used to identify the co-infection. This was followed
by an investigation on EBV oncogenes (BARF-1,
LMP-1 and EBNA-1) expression using immuno-
blotting and immunohistochemistry. This expression
would reflect the transformation mechanism of cer-
vical cells.
Since EBV could play an important role in Naso-
pharyngeal carcinoma and Burkitt’s lymphoma highly
frequent in Algeria, Our hypothesis was a possible
co-infection by HPV and EBV in Algerian SCC and
cervical lesions.Results
Detection of HR-HPV and EBV in SCC biopsies
Fifty eight biopsies of SCC from Algerian women were
analyzed to assess the presence of low and high-risk
HPV strains. PCR and Hybrid Capture 2 (HC2) tests
revealed that out the 58 studied samples 51 (88%) were
positive to HR-HPV strains and 7 (12%) were HPV
infection free. Among these HPV cases, 40 biopsies were
exclusively infected by high-risk HPV strains and 11 were
co-infected with high- and low-risk HPV (Figure 1).
In the same biopsies, the EBV genome was detected
by PCR amplification of the entire EBV-encoded BALF1
gene. The PCR product (BALF1 sequence of 660 bp)
was confirmed by Southern blot hybridization using the
random primer kit with 32P-labeled BamH1-A fragment
as a probe (Figure 2). As illustrated in Figure 1, 69%
(40/58) cases of SCC cervical biopsies were positive to
BALF1 sequence. EBV BALF-1 was present in only one
case that was HPV negative. 67.2% (39/58) were co-
infected with both viruses. 20.7% (12/58) were only
HPV infected. Co-infections with HPV and EBV were
detected more frequently in CIN-2/3 lesions and SCC
groups than in NC and CIN-1 groups (p < 0.05). In
terms of co-infection, there was no significant difference
between NC and CIN-1 groups.
PCR detection of HR-HPV and EBV in cervical lesions and
in normal patients
Using PCR and HC2, 21 CIN-2/3 and 16 CIN-1 lesions
and 14 normal tissue samples were investigated for HPV
genome. The two methods showed a good correlation.
95% (20/21) CIN-2/3 cases were infected by HR-HPV
compared to 40% (8/21) were co-infected with EBV.
Among the 16 CIN-1 cases, HR-HPV was present in
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Figure 2 Detection of EBV BALF1 gene by PCR. Amplified PCR products were electrophoresed and the presence of BALF1 sequence [39] was
confirmed by hybridization with 32P labeled BamH1-A fragment used as a probe. A: lanes 1-8 for tumor samples and B: lanes 9-16 for
precancerous lesions. B95-8 DNA and H2O were used as positive and negative controls respectively.
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remaining twenty three EBV free cases (CIN-1 and
CIN-2/3) were infected with either high or/and low risk
HPV strains. Among the fourteen normal cervix sam-
ples, only two were HR-HPV positive and only one was
co-infected (Figure 1).
Transcriptional and translational expression of EBV in
SCC cases
Limited by tissue specimens, the mRNA (LMP-1) and
protein (BARF-1) expression of EBV oncogenes was
assessed in only 23 out of 58 samples. However, all the
three proteins (BARF-1, LMP-1 and EBNA-1) were
immunohistochemically assessed in 45 out 58 of SCC
biopsies (Table 1).
As shown in Figure 3, the LMP-1 transcript was about
200 bp which was spliced from the 406 bp DNA
sequence (see Material and Methods). Using immu-
noblotting technique, BARF-1 protein was detected in
only 21.7% (5/23) of SCC biopsies analyzed from 50 μg
cellular extract (Figure 4). We also examined the tran-
scriptional and translational expression of HPV and
EBV oncogenes (LMP-1 and BARF-1) by immunohisto-
chemistry (IHC) (Figure 5). IHC analysis has allowed
the identification of HPV and EBV products. As shown
in Figure 5D, HPV was expressed in SCC biopsies. EBV
antigens, EBNA-1 and LMP-1, were present as a brown
nuclear and membrane staining (Figure 5B and C
respectively). EBNA-1 protein was detected in 34.7%Table 1 Relationship between the detection of EBV oncoprote
both HPV and EBV in malignant cervical biopsies
EBV and HPV genomes detection by PCR: 23 SCC LMP-1 de
14/23 HPV + EBV+
8/23 HPV + EBV-
1/23 HPV-EBV+(8/23). While IHC analysis showed 26% (6/23) LMP-1
positive cases (Figure 5C). Negative squamous carci-
noma cells for EBNA-1 and LMP-1 proteins are shown
in Figures 5E and F respectively.
Discussion
Our findings point out that most patients with either SCC
or cervical lesions are HR-HPV infected. To our surprise,
EBV-HPV co-infection was detected in the majority (67%)
of cervical carcinoma among the Algerian women in-
volved in this study. The presence of EBV was found in
69% of cervical cancer biopsies, suggesting its possible
association with the development of cervical cancer. This
is in agreement with previous reports [2,23,24]. However,
other researchers, using in situ hybridization, reported
controversial results [31-33]. Furthermore, Sasagawa et al.
[24] demonstrated, by RNA in situ hybridization, the pre-
sence of EBV and the expression of EBV genes, EBER-1,
LMP-1 and EBNA-1, in cervical biopsies.
Using immunohistochemistry technique, to our know-
ledge, we are the first to detect EBV antigens in the cervix
tissue. The difference in our results between the PCR
method and protein detection has three possible explana-
tions; (i) DNA amplification using PCR is a more sensitive
technique than the detection of antigens using Immu-
nohistochemistry or immunoblotting, (ii) EBV genome is
present but its genes are not abundantly expressed in
EBV-infected cells and (iii) a contamination by EBV-
positive B lymphocytes infiltrating the connective tissue orins (LMP-1 and BARF-1) and the presence of either or
tection by RT-PCR BARF-1 detected by Western blotting
7 LMP1+ 3 BARF1+
7 LMP1- 2 BARF1+
Negative Negative
Negative Negative
M    C- 1     2    3  4 5 6 7
406b
200b
Figure 3 Transcriptional expression of LMP-1. A 406-bp PCR amplified fragment corresponding to the LMP-1 DNA sequence, and a 200-bp
RT-PCR amplified fragment corresponding to the LMP-1 mRNA sequence. Lanes 1, 2 and 7 are positive signals. M: DNA fragments molecular
markers. C-: negative control.
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lesions. PCR results on their own merely indicate the pre-
sence of EBV in the cervix tissue but not necessarily in
the epithelial cells.
Our data suggest that co-infection with EBV and HR-
HPV may be of cervical significance in the ethiopatho-
genesis of uterine cervical cancer. However, few cells in
cervical tissue were infected by EBV and harbor EBV
LMP-1 protein (Figure 5). The expression of LMP-1 and
EBNA-1 in SCC may lead to the destruction of cancer
cells as they are targets for EBV-specific cytotoxic T
lymphocytes. Such process has been reported in gastric
[12] and Burkitt lymphomas [10]. However, the cervix is
histologically different from lymphoid tissues which are
localized very far from the cervical epithelium by thick
myometrial tissue of the cervix. The same situation has
been observed in HPV infection where E6-E7 oncogenes
are frequently expressed in cervical neoplastic lesions
and which are equally targets for cytotoxic T lympho-
cyte response in patients with cervical neoplasia [34].
EBV DNA has been shown in the exfoliating cells [28].




Figure 4 Detection of BARF-1 protein by Western blotting. Immunoblo
of protein extract as measured by a Biorad protein assay were deposited o
transferred onto nitrocellulose paper. BARF1 protein encoding 29 kDa (p29
(p29) produced by the BARF-1 recombinant adenovirus system was used aexpress its late antigens suggesting an association be-
tween EBV replication and epithelial differentiation [35].
Infectious EBV able to transform B lymphocytes has
been isolated from cervical washes from women reco-
vering from EBV mononucleosis infection or EBV-sero-
positive with no acute infection. Several studies showed
that EBV infection is sexually transmitted targeting the
uterine cervix [5,36-38].
In this study, EBV latent genes were expressed in some
squamous epithelia. The cervix might be a site for chronic
EBV shedding in a similar manner to the nasopharynx. It
is widely accepted that EBV infects B lymphocytes
through CD-21 (EBV/C3d) receptor [27] which are
equally present in cervix cells. The squamocolumnar junc-
tion of the cervix is the area where tissue repair and
inflammation frequently occur, and where cervical malig-
nancies associated with HPV infection develop. Similarly,
chronic cervicitis also may help the EBV infection [4]. The
low rate of EBV infection in normal cervixes and in pre-
cancer lesions compared with SCC cases of patients used
in this study suggests that EBV may play a role in late cer-
vical carcinogenesis. Further investigation is required to             4             5              6           7
tting of BARF-1 on seven cervical tumor biopsies. Fifty micrograms
nto 12% polyacrylamide gel and electrophoresed. Proteins were
) was revealed by PepIII rabbit polyclonal anti-BARF-1. BARF-1 protein
s a positive control indicated in first lane as BARF1.
A B C
D E F
Figure 5 Detection of HPV and EBV antigen by Immunohistochemistry. Immunohistochemistry analysis was performed on sections of cervix
tissue samples embedded in paraffin. HPV and EBV antigens were detected by peroxidase mediated DAB-staining (Brown). All samples were
counterstained with hematoxylin-eosin and then observed under a light microscope (original magnification 200x). Positive response is marked
with a white arrow. A: Squamous-cell carcinoma observed by heamatoxylin-eosine staining. B: Squamous carcinoma cells positive to EBNA-1
revealed by monoclonal anti-EBNA-1 antibody (OT-1). C: Squamous carcinoma cells positive to LMP-1 revealed by monoclonal anti- LMP-1
antibody (S12). D: Cytoplasmic and nuclear HPV staining with monoclonal antibodies (K1H8), which recognize HPV type 6, 11, 16, 18, 31, 33, 42,
51, 52, 56 and 58. E: Squamous-cell carcinoma negative to EBNA-1. F: Squamous-cell carcinoma negative to LMP-1. Weak staining of rare lymphocytes,
the tumor cells are negative for LMP1.
Figure 6 Flow chart showing the organization of HPV and EBV
detection and expression in squamous cell carcinoma (SCC)
cases by PCR using MY consensus primers and by Digene
Hybrid Capture II (HC II). The Epstein-Barr virus (EBV) was detected
by PCR using primers that amplify the entire BALF-1 gene. EBV
expression was investigated by LMP-1 Reverse Transcription-PCR,
BARF-1 Immunoblotting and LMP-1 and
EBNA-1 Immunohistochemistry.
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for the development of cervical cancer. EBV may be ac-
ting as a cofactor with another carcinogenic agent(s),
possibly human papillomaviruses, in the final invasive
cancer progression.
Conclusion
Preliminary presented results of EBV and HR-HPV co-
infection in Irish, North American, Thailand and Japanese
SCC cases were recently reported [2,3]. In our hands we
showed that most Algerian SCC patients were HPV-EBV
co-infected. A lesser degree of co-infection was observed
in pre-cancerous lesions of the cervix. A possible joint
effect of the two viruses on cervix tumor development
should be considered. Such hypothesis is strengthened by
EBV oncogene expression. It is clear that the presence of
EBV and its relationship with HPV in cervical oncogenesis
need to be further investigated.
Materials and methods
Samples
One hundred and nine cervix specimens taken from
female patients attending a gynecological department in
Algiers (Algeria) were randomly selected and enrolled
for EBV and HPV-DNA detection and genotyping
(Figure 6). We obtained from the Scientific Council
of the Faculty of Natural Sciences and Life, University
Setif-1 (Algeria) permission to investigate on human
samples, as required by the Helsinki declaration respec-
ting ethical principles for medical research, including
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CSF/SNV/2013). Patients were asked to participate in the
study, and informed consent was obtained for HPV
testing. They were classified as follows: Group 1 was com-
posed of 58 patients having invasive or in situ squamous-
cell carcinoma (SCC) of the uterine cervix. When the
tumor became evident, biopsies were freshly obtained
from these women immediately after surgery and were
snap-frozen in liquid nitrogen, transported to the labora-
tory and then stored at −80°C until processed. Histological
grading was performed by an experienced pathologist.
Each biopsy was cut with sterile blades, homogenized and
divided into three fractions; used respectively for RNA,
DNA, and protein preparations. Group 2 were 16 patients
with low-grade lesions (Cervical intraepithelial neoplasia-1
(CIN-1), condyloma, and cervicitis). Group 3 were 21
women with CIN-2/3 (known as mild and severe dys-
plasia). The samples of groups 2 and 3 were collected
from the apparently malignant zone. The samples were
then placed into a one ml tube of the transport medium
(ViraPap/Viratype transport medium, (Digene, Silver
Spring, MD)) and stored at −20°C until processing. Group
4 were 14 cases of normal cervixes obtained by scraping
the junction area of healthy women undergoing routine
cervical screening. Conventional cytology was performed
for this group.
DNA extraction and purification
Tissues were cut using sterile blades in a lysis buffer
(10 mm Tris, pH 7.4, 50 mm EDTA, 150 mm NaCl, 1%
sarcosyl) and treated with RNase A (10 mg/ml) for two
hours at 37°C. DNA was obtained after proteinase K
digestion, by phenol-chloroform extraction, ethanol pre-
cipitation and solubilized in 20 μl TE buffer (10 mm Tris–
HCl, pH 8.0; 1 mm EDTA). DNA quantities and purity
were assessed by spectroscopy.
Hybrid Capture 2 (HC2)
The HC2, a standardized US FDA-approved test has
been employed to detect one or more of 13 carcinogenic
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
and 68). This enzyme-linked immunosorbent assay is
based on a sandwich hybridization followed by a non-
radioactive alkaline phosphatase reaction following the
manufacturer’s instructions.
Polymerase chain reaction for detection of HPV DNA and
β-globin
Specimens were subjected to PCR with general HPV
primers using conventional L1 consensus primers, MY11
(GCMCAGGGWCATAAYAATGG) and MY09 (CGTC
CMARRGGAWACTGATC). The assays were conducted
according to the manufacturer’s protocol (Digene SHARP
Signal™ System).EBV-DNA identification by Southern blotting
As previously published by our group [39], EBV PCR
was performed in 25 μl reaction mixture containing Taq
polymerase buffer (10 mM Tris–HCl, pH 8.3; 50 mM
KCl), 5 mM MgCl2, 200 mM of each deoxyribonucleic
triphosphate, and 250 nM of each primer and 1 micro-
gram of DNA sample. The whole BALF1 sequence was
amplified from the DNA extracts using two primers:
ALF1-S (GGGGATCCAATGAACCTGGCCATTGCTC
TG) (upstream) at position 165,517 of EBV genome and
ALF1-AS (CGGAATTCTTACAAAGATTTCAGGAAG
TC) (downstream) at position 164,858. These primers per-
mitted to amplify a fragment of 660 bp (the entire BALF-1
gene). Ten microliters of the amplified fragment were
loaded onto 2% agarose gel, electrophoretically separated
and revealed by ethidium bromide and then transferred
onto reinforced nitrocellulose membranes (Schleicher &
Schuell, Germany). Amplified fragment was detected by
hybridization using 32P-labeled-BamH1-A probe prepared
with a random primer DNA-labeling kit (Stratagene) [33].
The hybridization was carried out in a modified solution
described by Ausubel et al. [34] with 106 cpm/ml of the
labeled BALF1 probe.
RT-PCR
RNA was extracted from control and specimens with
Trizol reagent (Invitrogen) according to the manufac-
turer’s instruction. Total RNA was treated with DNase
(amplification grade Deoxyribonuclease I, Invitrogen). Re-
verse transcriptase PCR (RT-PCR) was carried out as
previously described [10]. LMP-1 was amplified with
primers 5′-CGGGATCCATGGAACGCGACCTTGAGAG
and 5′-CGGGATCCCAACAGAAGAGACCTTCTCT.
Western blotting analysis (immunoblotting)
Biopsy tissues were cut using sterile blades in lysis buffer,
RIPA (650 mM NaCl, 5 mM EDTA, 20 mM Tris pH 7.5,
1% Triton, 0.5% and 0.1% SDS), and treated with antipro-
tease [11]. The lysates were sonicated and stored at −80°C.
Lysates were first adjusted to containing equal amounts of
proteins (50 micrograms) measured by a Biorad protein
assay (Bio-Rad Laboratories, Inc.) then diluted with one
volume of gel sample buffer (0.2% Bromophenol blue, 4%
SDS, 200 mM DTT (dithiothreitol), 20% glycerol,
125 mM Tris–HCl, pH 6.8) and boiled for 5 min. Protein
samples were separated on 12% polyacrylamide dena-
turing gels and electrophoretically blotted onto reinforced
nitrocellulose as previously described. After transfer, the
filters were subsequently incubated overnight at 4°C with
anti-BARF-1 (anti-Pep 2A) [10]. The filters were then
washed and incubated for 1–2 hours at room temperature
with peroxidase labeled polyclonal anti-rabbit anti-human
immunoglobulin as a secondary antibody. The antigen-
antibody complexes were visualized using an enhanced
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ted by the manufacturer.
Immunohistochemical staining
Cervix tissues were formalin fixed, dehydrated in alcohol
and embedded in paraffin. Immunostaining was per-
formed according to the streptavidin-biotin peroxidase
complex method, using monoclonal antibodies against
HPV, LMP-1 and EBNA-1. Briefly, sections were cut to a
thickness of 4 μm, mounted on silane-treated slides
(Superfrost), and dried 1 hour at 60°C. All sections were
then deparaffinized in xylene, rehydrated through alcohol,
and washed in phosphate-buffered saline. This buffer was
used for all subsequent washes. Sections for LMP-1,
EBNA-1 and HPV detection were heated in a microwave
oven twice for 5 min in citrate buffer (pH 6.0). Mouse
monoclonal antibodies (at a dilution of 1:500) anti-LMP-1
(S12, BD Biosciences Pharmingen), and anti-EBNA-1
(sc-29; Santa Cruz; Germany) were used respectively as
the primary antibody and incubated overnight at room
temperature followed by a conventional streptavidin per-
oxidase method (DAKO, Denmark). Signals were deve-
loped with 3, 30-diaminobenzidine for 5 minutes and
counter-stained with hematoxylin. The results were scored
for the positive signals in tissue cells. The same samples
were sectioned at 4 μm thickness and routine hematoxylin-
and eosine-stained for histologic examination.
Abbreviations
HPV: Human papillomavirus; EBV: Epstein-Barr virus; SCC: Squamous-cell
carcinoma; CIN: Cervical intraepithelial neoplasia.
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